Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory <i>Mycobacterium avium</i> Complex Pulmonary Disease.

ABSTRACT:

Background

Amikacin liposome inhalation suspension (ALIS) is key for treating refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, microbiological efficacy by subtype remains unknown. The frequency and mechanism of amikacin (AMK) resistance during ALIS administration are also unclear.

Methods

We retrospectively analyzed data from refractory MAC-PD patients who received ALIS for at least 6 months as an adjunct to guideline-based therapy at the NHO Kinki Chuo Chest Medical Center. We investigated the efficacy of ALIS and analyzed gene expression and the frequency of AMK resistance.

Results

We enrolled 44 patients (median age, 72.0 years): 19 (43.2%) with the noncavitary nodular bronchiectatic (NC-NB) subtype and 25 (56.8%) with the cavitary

SUBMITTER: Kurahara Y 

PROVIDER: S-EPMC11920506 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature